pramlintide, an antidiabetic that modulates and slows stomach emptying, prevents postprandial rise in plasma glucagon, decreases appetite, and leads to decreased caloric intake and weight loss. ▪ INDICATIONS: This drug is used as an adjunct to insulin therapy to treat uncontrolled type 1 or type 2 diabetes. ▪ CONTRAINDICATIONS: Gastroparesis and known hypersensitivity to this drug or to metacresol prohibit its use. ▪ ADVERSE EFFECTS: Adverse effects of this drug include headache, fatigue, dizziness, nausea, vomiting, anorexia, abdominal pain, injection site reactions, hypoglycemia (while used with insulin), arthralgia, cough, pharyngitis, and systemic allergy.
